PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29665297-2 2018 In this study, we examined the effects of the fast-acting, beta1 selective blocker esmolol on systemic hemodynamics and leg muscle O2 saturation (near infrared spectroscopy, NIRS) during submaximal leg ergometry. esmolol 83-90 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 59-64 31514219-3 2019 Therefore, heart rate control may be necessary to prevent cardiovascular events.Esmolol and landiolol as ultrashort and rapid acting highly selective beta 1 -adrenergic blockers are of particular interest in the prevention and management of cardiac arrhythmias. esmolol 80-87 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 150-156 27451411-2 2016 Esmolol was introduced some three decades ago as a short-acting beta1-selective antagonist. esmolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 64-69 28035016-7 2017 Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-receptors in healthy humans. esmolol 60-67 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 147-152 28035016-10 2017 Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-adrenergic receptors. esmolol 60-67 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 147-152 27451411-8 2016 If cells were incubated for >=24 hours in the presence of >=1 muM esmolol, the levels of beta1-adrenergic-but not of beta2-adrenergic-receptors increased. esmolol 72-79 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 95-100 19150530-12 2009 The ultra-short-acting beta-1 selective adrenergic antagonists esmolol and landiolol can be safely used perioperatively in patients with airway hyperreactivity. esmolol 63-70 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 23-29 26121122-9 2015 Five prospective studies (two randomized) assessed the hemodynamic effects of the beta1-blocker esmolol. esmolol 96-103 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 82-87 23902616-5 2013 The adrenergic beta-1 antagonist esmolol was injected through central venous catheter to reduce heart rate by 20% from baseline. esmolol 33-40 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 15-21 19122550-1 2009 BACKGROUND AND OBJECTIVE: It is known that esmolol, a short-acting beta1-blocker, reduces anaesthetic requirement. esmolol 43-50 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 67-72 7502643-5 1995 Selective beta 1 antagonists (i.e., esmolol) may need to be titrated with a direct vasodilator (i.e., nitroprusside) to manage hypertension and tachycardia. esmolol 36-43 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 10-16 12197593-1 2002 In recent years there has been renewed interest in beating heart surgery using the ultra-active and selective beta1-blocker, esmolol. esmolol 125-132 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 110-115 11602813-2 2001 Celiprolol is a beta 1 -receptor blocker with vasodilating properties, whereas esmolol is an ultra-short-acting beta 1 -blocker. esmolol 79-86 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 112-118 16215384-1 2005 OBJECTIVE: Since beta-blocker therapy is known to be effective in patients with an injured heart, such as infarction, we designed the present study to examine the protective effects of infusion of the beta1-selective blocker esmolol on myocardial function in peritonitis-induced septic rats using an isolated working heart preparation. esmolol 225-232 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 201-206 12460877-3 2002 METHODS AND RESULTS: We investigated the consequences of short-term intravenous administration of an alpha-1 adrenergic agonist, phenylephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years. esmolol 180-187 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 150-156 12565117-4 2002 We concluded that the beta(1) selective, ultra-short acting beta-blocker, esmolol, can be used intraoperatively when both conditions are present. esmolol 74-81 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 22-29 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 88-94 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 201-207 1688693-3 1990 Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation. esmolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 30-36